Logo image of ASLN

ASLAN Pharmaceuticals Ltd (ASLN) Stock Fundamental Analysis

NASDAQ:ASLN - Nasdaq - US04522R2004 - ADR - Currency: USD

0.6  -0.1 (-14.27%)

After market: 0.56 -0.04 (-6.67%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ASLN. ASLN was compared to 572 industry peers in the Biotechnology industry. ASLN may be in some trouble as it scores bad on both profitability and health. ASLN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ASLN has reported negative net income.
ASLN had negative earnings in each of the past 5 years.
ASLN had a negative operating cash flow in each of the past 5 years.
ASLN Yearly Net Income VS EBIT VS OCF VS FCFASLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

ASLN's Return On Assets of -93.07% is on the low side compared to the rest of the industry. ASLN is outperformed by 75.96% of its industry peers.
ASLN has a Return On Equity of -806.53%. This is amonst the worse of the industry: ASLN underperforms 82.40% of its industry peers.
Industry RankSector Rank
ROA -93.07%
ROE -806.53%
ROIC N/A
ROA(3y)-72.62%
ROA(5y)-99.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASLN Yearly ROA, ROE, ROICASLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASLN Yearly Profit, Operating, Gross MarginsASLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

There is no outstanding debt for ASLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASLN Yearly Shares OutstandingASLN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 100K 200K 300K 400K
ASLN Yearly Total Debt VS Total AssetsASLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

ASLN has an Altman-Z score of -9.77. This is a bad value and indicates that ASLN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ASLN (-9.77) is worse than 77.35% of its industry peers.
A Debt/Equity ratio of 3.84 is on the high side and indicates that ASLN has dependencies on debt financing.
ASLN has a Debt to Equity ratio of 3.84. This is amonst the worse of the industry: ASLN underperforms 82.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.84
Debt/FCF N/A
Altman-Z -9.77
ROIC/WACCN/A
WACCN/A
ASLN Yearly LT Debt VS Equity VS FCFASLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ASLN has a Current Ratio of 2.26. This indicates that ASLN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.26, ASLN is doing worse than 74.39% of the companies in the same industry.
A Quick Ratio of 2.26 indicates that ASLN has no problem at all paying its short term obligations.
The Quick ratio of ASLN (2.26) is worse than 73.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 2.26
ASLN Yearly Current Assets VS Current LiabilitesASLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

ASLN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -173.28%.
EPS 1Y (TTM)-173.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ASLN will show a very strong growth in Earnings Per Share. The EPS will grow by 30.68% on average per year.
Based on estimates for the next years, ASLN will show a very strong growth in Revenue. The Revenue will grow by 36.90% on average per year.
EPS Next Y58.45%
EPS Next 2Y30.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y36.9%

3.3 Evolution

ASLN Yearly Revenue VS EstimatesASLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
ASLN Yearly EPS VS EstimatesASLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ASLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASLN Price Earnings VS Forward Price EarningsASLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASLN Per share dataASLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ASLN's earnings are expected to grow with 30.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ASLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASLAN Pharmaceuticals Ltd

NASDAQ:ASLN (7/18/2024, 8:00:00 PM)

After market: 0.56 -0.04 (-6.67%)

0.6

-0.1 (-14.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-31 2024-05-31/amc
Earnings (Next)08-09 2024-08-09/bmo
Inst Owners0.84%
Inst Owner Change-99.33%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.70M
Analysts82.5
Price Target77.52 (12820%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.65%
Min EPS beat(2)68.77%
Max EPS beat(2)86.52%
EPS beat(4)3
Avg EPS beat(4)39.54%
Min EPS beat(4)-14.56%
Max EPS beat(4)86.52%
EPS beat(8)5
Avg EPS beat(8)20.2%
EPS beat(12)6
Avg EPS beat(12)11.09%
EPS beat(16)7
Avg EPS beat(16)-18.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)700%
PT rev (3m)700%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.27
EV/EBITDA N/A
EPS(TTM)-11.15
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.07%
ROE -806.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.62%
ROA(5y)-99.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 3.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.26
Quick Ratio 2.26
Altman-Z -9.77
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8.6%
Cap/Depr(5y)11.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-173.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.68%
EPS Next Y58.45%
EPS Next 2Y30.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y36.9%
EBIT growth 1Y-41.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.96%
OCF growth 3YN/A
OCF growth 5YN/A